When a test determined that Walter had hemophilia, his Omaha owner joined a group seeking to raise $50,000 for a clinical ...

Pfizer opted to discontinue the product for "several reasons," including limited interest from patients and physicians in gene therapies for hemophilia.

Qure's stock rises on Huntington's therapy progress and strong gene therapy pipeline. Learn about QURE stock's cost-cutting ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

The expansion of the advanced therapy medicinal products market is primarily fueled by the increasing incidence of chronic diseases. The rising prevalence of genetic disorders and cancer, along ...

近日，据Endpoints ...